Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J1S-MC-JP04: Abemaciclib + irinotecan + temozolomide in relapsed or refractory Ewing's sarcoma
2023-506772-28-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of abemaciclib in Ewing sarcoma of bone and Ewing sarcoma, sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Mar 2024; status: completed.
02
Drugs
abemaciclib
03
Conditions
Ewing sarcoma of boneEwing sarcoma
Beyond the preview
Go deeper on 2023-506772-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506772-28-00.